*Streptococcus agalactiae* (Group B *Streptococcus* \[GBS\]) is a major cause of neonatal morbidity and mortality worldwide[@b1][@b2]. While the incidence of GBS early-onset sepsis has decreased substantially in the United States following the implementation of universal screening and intrapartum antimicrobial prophylaxis[@b3][@b4], these represent resource-intensive policies that are subject to missed opportunities for prevention[@b5][@b6]. Because of these limitations, improved methods for prevention of GBS disease are urgently needed. Immunization with capsular polysaccharide (CPS)-protein conjugates can induce serotype-specific immunity[@b7], and candidate GBS conjugate vaccines are currently being tested in clinical trials[@b8].

The serotype of a GBS strain is determined by the genes in the *cps* locus, and 10 distinct serotypes (Ia, Ib, II-IX) have been described to date[@b9][@b10]. Understanding the serotype distribution of GBS in both disease and colonization states is crucial to inform rational vaccine policies and to detect events such as capsular switching[@b11][@b12] and serotype replacement. Capsular typing of GBS is generally performed using latex agglutination with type-specific antibodies, though both multiplex PCR[@b13][@b14][@b15] and flow cytometry[@b16] strategies have been described. More recently, whole-genome sequences have been used to determine GBS serotypes[@b17]. Here we describe a novel TaqMan-based real-time PCR strategy for serotyping GBS based on detection of specific *cps* locus sequences and demonstrate its applicability using both a defined set of strains from a reference laboratory and a set of primary clinical isolates.

Materials and Methods
=====================

Bacterial strains and growth conditions
---------------------------------------

A total of 68 clinical GBS isolates were included in this study. Of these, 47 *S. agalactiae* serotype reference stains were provided by the *Streptococcus* laboratory at the Respiratory Diseases Branch of the Centers for Disease Control and Prevention (CDC). For some isolates, multilocus sequence type (MLST) determination was determined by the *Streptococcus* reference laboratory using established protocols (<http://pubmlst.org/sagalactiae/>). The remaining 21 isolates were deidentified sterile site isolates collected between 2010 and 2015 in New York City. All specimens were cultured on trypticase soy (TS) or 5% sheep blood agar plates at 37 °C and then grown overnight in TS media at 37 °C.

Serotyping by latex agglutination
---------------------------------

All GBS isolates were serotyped by latex agglutination with the Immulex Latex Agglutination Streptococcus B kit (Staten Serum Institute; Copenhagen, Denmark) according to the manufacturer's instructions. Briefly, 10 μl of the latex reagent was added to a single colony of GBS suspended in 10 μl of saline. The reaction was rotated and interpreted as positive if agglutination was visible after 30 seconds.

TaqMan real-time PCR serotyping
-------------------------------

Primers and probes were designed to amplify unique regions of the polysaccharide capsular genes of each of the serotypes of *S. agalactiae* ([Table 1](#t1){ref-type="table"}). In order to generate these primer/probe sets, DNA sequences from specific capsular polysaccharide (cps) operons were obtained from National Center for Biotechnology Information databases ([Table 1](#t1){ref-type="table"}). Trimmed predicted *cpsE*-*cpsL* regions were aligned with using the CLUSTALW algorithm ([Supplemental File 1](#S1){ref-type="supplementary-material"}). Specific primer and probe sequences and target regions were hand-selected from this multiple alignment of all 10 cps operons and are listed in [Table 1](#t1){ref-type="table"}. Oligonucleotides and probes were obtained from Integrated DNA Technologies (Coralville, IA). Oligonucleotides were unmodified and desalted, and probes were labeled with a fluorescent probe (5′ 6-carboxyfluorescein (6-FAM)) and two quenchers (internal ZEN^TM^, and 3′ Iowa Black® FQ) and purified by high-pressure liquid chromatography.

Genomic DNA was extracted from overnight cultures of GBS using the Qiagen DNeasy Blood and Tissue Kit according to the manufacturer's instructions. PCR reactions were performed in a final volume of 20 μl and consisted of 10 μl Taqman Universal Mastermix (Applied Biosystems), 7.4 μl sterile water, 0.2 μl forward primer (100 μM stock), 0.2 μl reverse primer (100 μM stock), 0.2 μl probe (100 μM stock), and 2 μl GBS DNA (25 ng/μl, unless otherwise indicated in the text.) Triplicate reactions were performed on a StepOne Plus thermal cycler (Applied Biosystems) and analyzed using StepOne software. Reaction parameters were as follows: initial incubation at 50 °C for 2 minutes; initial denaturation at 95 °C for 10 minutes; 35 cycles of PCR at 95 °C for 15 seconds and 60 °C for 1 min. Positive reactions were defined as a cycle threshold (C~T~) \< 30 for 50 ng DNA template/reaction. Negative control reactions (no DNA template) were included with every run. Results were compared to latex agglutination.

Reaction sensitivity and interference by non-targeted strains
-------------------------------------------------------------

Sensitivity was evaluated by determining the cycle threshold on 10-fold serial dilutions of bacterial DNA from 5 ng to 50 pg per reaction. Potential interference was assessed by real-time PCR using each primer/probe set under the conditions above with a mixture of chromosomal DNA from all ten GBS serotypes (strains AR959 - AR968) at a final amount of 25 ng for each strain (250 ng total DNA) per reaction as template.

Results
=======

Accuracy of real-time PCR serotyping using a validation set
-----------------------------------------------------------

We used a set of 47 validation strains (≥3 per serotype) from the CDC *Streptococcus* laboratory to determine whether the primer/probe combinations listed in [Table 1](#t1){ref-type="table"} could be used for accurate serotyping. In all cases, there was detection of the predicted sequence using the real-time PCR protocol ([Table 2](#t2){ref-type="table"}) and no positive reactions with any of the other serotype primer/probe combinations (not shown). We confirmed the serotype of each of the 47 strains by latex agglutination, and there was 100% concordance between the PCR-based and latex agglutination methods for the validation set.

Serotyping of clinical isolates
-------------------------------

We used the real-time PCR serotyping assay on a collection of 21 clinical sterile-site GBS isolates ([Table 3](#t3){ref-type="table"}). In 21/21 (100%) of cases, a single serotype was detected at C~T~ \< 30, and in all of those, the result was confirmed by latex agglutination.

Sensitivity of real-time PCR serotyping and potential interference
------------------------------------------------------------------

In order to determine the sensitivity of the real-time PCR protocol, we performed serial dilutions of the extracted DNA from 20 of the validation strains, from 5 ng to 50 pg per reaction. As predicted, C~T~ increased as the total amount of bacterial DNA template in the reaction decreased ([Fig. 1](#f1){ref-type="fig"}), though the majority of strains remained under the 30 cycle threshold, even at 50 pg per reaction. For all primer sets, detection of target sequences (C~T~ \< 30) was robust to the inclusion of an excess of non-targeted GBS DNA.

Discussion
==========

Clinical microbiology laboratories routinely identify GBS but do not typically report serotype data. However, as the development of vaccines that target a subset of the ten known GBS serotypes proceeds, it will become increasingly important to understand the distribution of vaccine and non-vaccine serotypes and to monitor for capsular switching and serotype replacement. Non-nucleic acid-based laboratory methods for GBS serotyping techniques can be labor intensive and expensive, may require high-titer serotype-specific antisera and can create an added barrier for performing GBS serotype prevalence studies. Latex agglutination kits may be used for GBS serotyping in reference laboratories but are costly and not routinely available.

Molecular capsular typing techniques, including multiplex PCR[@b13][@b14] and targeted analysis of whole genome sequences[@b17], may be advantageous because of adaptability to newly available sequence information and relative ease of performance. In one prior study, real-time PCR was reported to distinguish among serotypes Ia, Ib, and III only[@b18]. We designed custom primer-probe sets for detection of all ten GBS serotypes. Unlike many prior methods, serotyping by real-time PCR is not based on operator interpretation of biochemical reactions and allows for specific identification of a GBS serotype despite interference from other bacterial DNA. Although the current assay is likely too technically demanding for routine laboratory adoption, it may be useful in the context of epidemiologic studies as an alternative to existing multiplex PCR assays. With further development, this novel method may allow for detection of GBS serotypes directly from clinical specimens without the need for culture. Limitations of this real-time PCR-based serotyping include an inability to identify new serotypes directly (as specific primer-probe sets are required for detection) and dependence on conservation of the targeted genetic regions within a particular serotype. Further validation of these primer-probe sets on a globally representative set of isolates is underway, as all of the tested strains originated in North America. Studies of larger, more diverse strain collections will be required to ensure that the primer-probe sets are sensitive and specific across an appropriate range of isolates.
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###### Target genes, primer and probe sequences for GBS serotyping by real-time PCR.

                               Sequence (5′-3′)                                                                                                            Target Gene                                                                                         Amplicon Size (bp)   NCBI Accession
  -------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ----------------
  Ia-F           GTTTAAAAATCCTGATTTTGATAGAATTTTAGCAGCTTTTAAC                                                                                                 *cpsH*                                                                                                   207             CP000114.1
  Ia-R        CTGATATTTTGAATATTATTATGCAAACAATAATAATATGTTCCCCCTA                                                                                                                                                                                                                            
  Ia-P         6-FAM-TCGTTGATT/ZEN/ATCGGTATAGTATCATTG GCT-IAbFQ                                                                                                                                                                                                                            
  Ib-F         GTATTAAATTCGTTATTTAGAAGTCCAGAATTTCATAGAGTCATTGC                                                                                               *cpsH*                                                                                                   195             FO393392.1
  Ib-R        GGCATAATAATATAGAAATCCTAAACAAGACAAAATAATTGCATTAAAC                                                                                                                                                                                                                            
  Ib-P          6-FAM-TGC ATT CAA/ZEN/TTCACTGGCAGTAGGG- IAbFQ                                                                                                                                                                                                                              
  II-F        CACATATATATTAAAGTTCACCCTAGAGATAACATTGACTACTCTAATC                                                                                              *cpsK*                                                                                                   151           AAJO01000077.1
  II-R             CTAATGCCGTGGAAAAATATGTAATCCCAACATCAAATT                                                                                                                                                                                                                                 
  II-P        6-FAM-AATGCAACA/ZEN/GTAATACAAAGGAACATC CCT- IAbFQ                                                                                                                                                                                                                            
  III-F                   GGAATTGTTCTTTATTTTTCTGCCT                                                                                                          *cpsI*                                                                                                   170             AL766849.1
  III-R           ACTATACCAAAAGTTGAGAATAATAATACAATACTCCAATGA                                                                                                                                                                                                                               
  III-P       6-FAM-ATGTTACAC /ZEN/GCTCTTTGAGGAAATAGATCC- IAbFQ                                                                                                                                                                                                                            
  IV-F       GAAGAAAATATATATTTGCCATACAGTATATCATCTCCTTATTACAATTATC                                                                                            *cpsK*                                                                                                   159             AF355776.1
  IV-R        CATAGAATACCTTCTTTATTGGTACGTTTACATAAATCATCAATATTAAC                                                                                                                                                                                                                           
  IV-P       6-FAM-AGGGAACAG /ZEN/AGGAGATCAATAATTATATTGGC- IAbFQ                                                                                                                                                                                                                           
  V-F             CAAAATTCAATGAGAGAATGTTGTATTTTTTTGAGGCAATTC                                                                                                 *cpsO*                                                                                                   153             AE009948.1
  V-R              CAATCATCTTCCCACATATATCTATTCCACCAAATACTTC                                                                                                                                                                                                                                
  V-P       6-FAM-ATTTTCCAC /ZEN/ATAATACATCTTTAATCTCTGCTG T- IAbFQ                                                                                                                                                                                                                         
  VI-F                 GACAGTCTATTACGAAAGTATAAGAGCGATT                                                                                                       *cpsH*                                                                                                   219             HF952106.1
  VI-R           AGCTTGTAGATTATCCTGTTTTGTTTGATAGCTTCTCTATATAG                                                                                                                                                                                                                              
  VI-P        6-FAM-CCCTCCAGT/ZEN/GTGGGAATATTTTTAGGTTCAC- IAbFQ                                                                                                                                                                                                                            
  VII-F            GAGGGCTTACCTCACGACAGGAGAAGTAAAAAATATAAAG                                                                                                  *cpsK*                                                                                                   160             AY376403.1
  VII-R                GCTGCGTTAATAACAATACTGACTTTGGAGC                                                                                                                                                                                                                                     
  VII-P        6-FAM-AGTCTTACC/ZEN/CAAGAACAAAAGTCTCTGATT- IAbFQ                                                                                                                                                                                                                            
  VIII-F         GACTAATGGTTAAGTATGCTAACTTGCTAATTTGTGATAGTAA                                                                                                 *cpsR*                                                                                                   152              AY375363
  VIII-R           CTTGTCCTTAAAATTGTGTTTTGACTTTGTCAGATCAGTC                                                                                                                                                                                                                                
  VIII-P       6-FAM-ATGCTCCTA/ZEN/AAACAACCTACATCGCCTATG- IAbFQ                                                                                                                                                                                                                            
  IX-F               CATTGAGCAAAGAGAAAACAGTATATGTCAAAGGGC                                                                                                    *cpsO*                                                                                                   128            CGBY01000002
  IX-R             ATGTTCAAGGATAAAATCTCTATTATGTTGCATTGCTTCA                                                                                                                                                                                                                                
  IX-P         6-FAM-AGTACTACC/ZEN/AGACAGTCATACAAAGAGAAT- IAbFQ                                                                                                                                                                                                                            
                                                                     Sequences are presented 5\' to 3\' with probe modifications as indicated (6-carboxyfluorescein \[6-FAM\] fluorescent probe, internal ZEN^TM^ and Iowa Black^®^ FQ \[IAbFQ\] quenchers).                       

###### Cycle thresholds for real-time PCR serotyping of CDC validation strains.

  Strain        Serotype   MLST            C~T~
  ------------ ---------- ------- ----------------------
  20154637         Ia       ST1    19.40 (17.76--22.18)
  20155889         Ia      ST23    17.61 (16.61--18.17)
  20155226         Ia      ST19    17.56 (17.49--17.60)
  2008232728       Ia              18.22 (17.98--18.65)
  2014210282       Ia              18.55 (18.46--18.61)
  20153631         Ib       ST1    16.24 (15.77--16.60)
  20153550         Ib       ST8    17.62 (17.49--17.76)
  20155787         Ib      ST12    16.75 (16.52--17.12)
  2008232729       Ib              17.21 (17.08--17.41)
  2014210284       Ib              19.54 (19.17--19.93)
  20154198         II       ST1    16.83 (16.82--16.86)
  20155757         II      ST22    16.90 (16.68--17.09)
  20155810         II      ST28    16.33 (16.23--16.44)
  2008232738       II              19.76 (19.25--20.54)
  2014210280       II              17.54 (17.42--17.68)
  20154686        III      ST17    19.53 (18.99--20.60)
  20154526        III      ST19    18.23 (17.71--18.82)
  20155871        III      ST335   17.54 (16.34--18.23)
  2008232582      III              18.99 (18.34--19.67)
  2014210283      III              19.93 (19.87--20.29)
  20151912         IV      ST452   17.30 (16.53--17.93)
  20155826         IV      ST459   17.41 (16.95--18.10)
  20152623         IV      ST468   17.69 (17.55--17.85)
  2011201884       IV              19.93 (19.90--19.98)
  2014210293       IV              18.71 (18.66--18.78)
  20155749         V        ST1    15.45 (15.19--15.89)
  20155753         V       ST19    15.91 (15.63--16.22)
  20155859         V       ST26    15.25 (15.13--15.31)
  2008232731       V               18.45 (17.89--18.92)
  2014210268       V               18.13 (18.09--18.17)
  20156225         VI       ST1    18.66 (18.09--19.10)
  20155762         VI       ST1    18.16 (17.60--18.68)
  20154691         VI       ST1    17.51 (16.84--17.85)
  2010228816       VI              20.98 (20.55--21.29)
  2013225975       VI              21.42 (21.09--21.97)
  20154086        VII       ST1    16.55 (15.88--16.96)
  20154176        VII       ST1    17.11 (16.51--17.56)
  4832-06         VII              19.91 (19.50--20.49)
  2014201718      VII              19.45 (19.29--19.66)
  20140487        VIII             16.05 (15.13--17.01)
  20150287        VIII             16.06 (15.25--17.65)
  2014207299      VIII             14.80 (13.89--15.56)
  5030-08         VIII             18.24 (18.09--18.35)
  2013226269      VIII             23.08 (22.97--23.29)
  20155073         IX      ST130   16.73 (15.57--18.06)
  7509-07          IX              18.36 (18.34--18.39)
  2014203375       IX              17.77 (17.41--17.97)

Reported C~T~ is the mean of three technical replicates, with range given in parentheses. Serotype as determined by latex agglutination and MLST (when available) are indicated.

###### Real-time PCR serotyping of clinical GBS isolates is concordant with latex agglutination.

  Strain    Real-time PCR   Latex Agglutination
  -------- --------------- ---------------------
  AR611          IV                 IV
  AR618          III                III
  AR624          II                 II
  AR626          III                III
  AR629          IV                 IV
  AR630          Ib                 Ib
  AR631          III                III
  AR634          III                III
  AR667          III                III
  AR880          III                III
  AR905          Ia                 Ia
  AR1019         Ia                 Ia
  AR1021         III                III
  AR1036         Ia                 Ia
  AR1037         IV                 IV
  AR1046         III                III
  AR1049         Ia                 Ia
  AR1053         Ia                 Ia
  AR1054         III                III
  AR1055         III                III
  AR1056         III                III

A collection of 21 clinical isolates of unknown serotypes was tested by real-time PCR and by latex agglutination. All strains gave a single serotype by real-time PCR (C~T~ \< 30; range 15--23 for 50 ng template/reaction).
